Lupin has launched generic anti-diabetic tablets in the United States—dapagliflozin and metformin hydrochloride extended-release—after receiving FDA approval. The company says its product is bioequivalent to Xigduo XR, positioning the launch as a potential new option for diabetes patients seeking effective treatment in the US market.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
